Demographic and Clinical Characteristics of Patients with Sustained and Switching Treatments Using Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs: A Multicenter, Observational Cross-Sectional Study for Rheumatoid Arthritis

Simple item page
dc.contributor.authorAtaman S.
dc.contributor.authorSunar I.
dc.contributor.authorBodur H.
dc.contributor.authorMelikoglu M.A.
dc.contributor.authorCay H.F.
dc.contributor.authorCapkin E.
dc.contributor.authorAkgul O.
dc.contributor.authorCevik R.
dc.contributor.authorGogus F.
dc.contributor.authorKamanli A.
dc.contributor.authorYurdakul F.G.
dc.contributor.authorGurer G.
dc.contributor.authorYagci I.
dc.contributor.authorRezvani A.
dc.contributor.authorDuruoz M.T.
dc.date.accessioned2024-07-22T08:04:45Z
dc.date.available2024-07-22T08:04:45Z
dc.date.issued2022
dc.description.abstractIntroduction: Rheumatoid arthritis is a chronic inflammatory disease with different disease activity grades. Several registries have been designed to determine the appropriate regimens of disease-modifying antirheumatic drugs to obtain sustained clinical remission. We examined epidemiological and clinical characteristics of rheumatoid arthritis patients using a clinical registry database (BioSTaR) and analyzed the differences in patients with sustained and switched therapies. Methods: A multicenter, observational cross-sectional study for rheumatoid arthritis was performed between February 2019 and September 2020 using the BioStaR-RA registry. Demographic and clinical characteristics were prospectively recorded into a specifically designed electronic database. The patients were divided into three groups due to the heterogeneity of the study cohort. Patients were grouped as Group I (Initial; within the first 6 months of treatment with biological/targeted synthetic drugs), Group ST (Sustained Treatment; any first drug lasting for at least 6 months without any change), and Group S (Switch; any switching to another drug). Comparative analysis was performed between sustained treatment (Group ST) and drug switching (Group S) groups. Results: The study included a total of 565 patients. The mean age was 53.7 ± 12.8 years, and the majority were female (80.4%). There were 104, 267, and 194 patients in Groups I, ST, and S, respectively. Erosive arthritis and hematological extra-articular involvement were more frequently detected in Group S than Group ST (p = 0.009 and p = 0.001). The patients in Group S had significantly higher disease activity scores (DAS28-CRP, CDAI, and SDAI) (p = 0.025, p = 0.010, and p = 0.003). There were significantly more patients with moderate disease activity in Group S (p < 0.05). Conclusions: The groups with sustained treatment and switching included patients with different disease activity status, although higher disease activity was determined in switchers. Overall, moderate disease activity and remission were the most common disease activity levels. Lower disease activity scores, lower hematologic manifestations, better functional status, and lesser radiographic damage are associated with sustained treatment. © 2021, The Author(s).
dc.identifier.DOI-ID10.1007/s40744-021-00403-y
dc.identifier.issn21986576
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12830
dc.language.isoEnglish
dc.publisherAdis
dc.rightsAll Open Access; Gold Open Access
dc.subjectabatacept
dc.subjectadalimumab
dc.subjectC reactive protein
dc.subjectcertolizumab pegol
dc.subjectcyclic citrullinated peptide antibody
dc.subjectdisease modifying antirheumatic drug
dc.subjectetanercept
dc.subjectgolimumab
dc.subjecthydroxychloroquine
dc.subjectinfliximab
dc.subjectleflunomide
dc.subjectmethotrexate
dc.subjectrheumatoid factor
dc.subjectrituximab
dc.subjectsalazosulfapyridine
dc.subjecttocilizumab
dc.subjecttofacitinib
dc.subjectadult
dc.subjectaged
dc.subjectalcohol consumption
dc.subjectArticle
dc.subjectbody mass
dc.subjectchronic obstructive lung disease
dc.subjectClinical Disease Activity Index
dc.subjectcomparative study
dc.subjectcontrolled study
dc.subjectcross-sectional study
dc.subjectDAS28
dc.subjectdata base
dc.subjectdemography
dc.subjectdiabetes mellitus
dc.subjectdisease activity
dc.subjectdisease duration
dc.subjecteducational status
dc.subjecterythrocyte sedimentation rate
dc.subjectfemale
dc.subjectHealth Assessment Questionnaire
dc.subjecthuman
dc.subjecthyperlipidemia
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmarriage
dc.subjectmorning stiffness
dc.subjectmulticenter study
dc.subjectobservational study
dc.subjectosteoporosis
dc.subjectprospective study
dc.subjectrheumatoid arthritis
dc.subjectSimplified Disease Activity Index
dc.subjectsmoking
dc.subjectvisual analog scale
dc.titleDemographic and Clinical Characteristics of Patients with Sustained and Switching Treatments Using Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs: A Multicenter, Observational Cross-Sectional Study for Rheumatoid Arthritis
dc.typeArticle

Files

Collections

Scopus Koleksiyonu